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Abstract: Little is known about intravenous thrombolysis (IVT) in acute ischemic stroke (AIS) patients
with pre-existing disability. Disabled patients are often excluded from IVT treatment. Previous studies
investigated the role of pre-existing disability on outcomes in AIS patients after IVT. However, no
studies have been conducted to date to determine whether IVT may improve clinical outcomes in
AIS patients with pre-existing disability. The aim of our study was to evaluate efficacy and safety of
IVT in patients with pre-existing moderate and moderately severe disability (pre-stroke modified
Rankin Scale score = 3 or 4) affected by AIS. This study was based on a retrospective analysis of a
prospectively collected database of consecutive patients admitted to the Udine University Hospital
with AIS from January 2015 to May 2018. The efficacy endpoints were the rate of favorable outcome
and rate of major neurological improvement. The safety endpoints were the rate of mortality at
three months, presence of intracranial hemorrhage (ICH), and presence of symptomatic intracranial
hemorrhage (sICH). The study population included 110 AIS patients with pre-existing moderate
and moderately severe disability, 36 of which received (IVT+) and 74 did not receive IVT (IVT−).
AIS disabled patients treated with IVT had higher rates of favorable outcome (66.7% vs. 36.5%,
p = 0.003) and major neurological improvement (39.4% vs. 17.4%, p = 0.01) compared to non-treated
ones. Two in three disabled patients returned to their pre-stroke functional status when treated with
IVT. Prevalence of three-month mortality, ICH, and sICH did not differ in the two groups. Disabled
patients affected by AIS significantly improved after IVT. Moderate and moderately severe disability
alone should not be considered, per se, as a contraindication to IVT treatment.
Keywords: acute ischemic stroke; intravenous thrombolysis; pre-existing disability; modified Rankin
Scale; outcomes
1. Introduction
In industrialized countries stroke is the second most important cause of mortality in the world
and the third in terms of disease burden, calculated as disability-adjusted life years (DALYs) [1,2].
Indications for use of intravenous thrombolysis (IVT) in patients with acute ischemic stroke (AIS)
changed over time and an increasing number of patients could undergo this safe and efficacious
treatment [3–5]. At this time, little is known about IVT in AIS patients with pre-existing disability.
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Patients who could not live alone without daily help of another person prior to stroke, e.g.,
patients with a modified Rankin Scale (mRS) score ≥3, are often excluded from IVT treatment because
of concerns about poor outcomes [6–10]. In fact, these patients account for only 10% of treated cases
according to international stroke registries [11,12]. To date, a few studies have been performed in
order to evaluate the role of pre-existing disability on outcomes in AIS patients after IVT. The authors
observed a higher rate of mortality in functionally dependent patients, while the risk of symptomatic
intracranial hemorrhage (sICH) did not increase in these subjects compared to independent patients
when treated with IVT [13–16]. However, no studies have been conducted in AIS patients with
pre-existing disability to determine whether IVT may improve clinical outcomes.
The aim of our study was to evaluate efficacy and safety of IVT in patients with pre-existing
moderate and moderately severe disability (defined as pre-stroke mRS score = 3 or 4), comparing the
clinical outcomes of treated patients with those of the untreated ones.
2. Methods
2.1. Patients
This study was based on a retrospective analysis of a prospectively collected database of
consecutive patients admitted to the Udine University Hospital because of AIS from January 2015 to
May 2018. Of 1392 patients admitted for AIS, 144 had a pre-stroke mRS score ≥3 and were suitable for
IVT treatment. Since no AIS patients affected by very severe pre-stroke disability (mRS score = 5) had
been treated with IVT, we excluded them from the study (n = 15). Nineteen additional patients were
excluded because of: (1) clinical conditions different from stroke that could have caused fluctuating
disability (n = 4); (2) treatment with endovascular thrombectomy in addition to IVT (n = 8); (3) loss
to follow–up (n = 7). The remaining sample of 110 AIS patients with a pre-stroke mRS score of 3 or 4
were included in the analysis and were stratified into 2 groups: AIS patients who received IVT (IVT+)
and those to whom IVT was denied because of a pre-existing disability (IVT−).
2.2. Data Collection
The following variables were collected: Age, sex, vascular risk factors, presence of cognitive
impairment, laboratory findings, and pharmacological treatment at admission. Data on causes of
pre-stroke dependency were acquired. The functional outcome was assessed by means of the mRS
score at admission, based on the pre-stroke disability, and 3 months after the stroke. Stroke severity
was determined with the National Institute of Health Stroke Scale (NIHSS) at admission and discharge.
The presence of intracranial hemorrhage (ICH) was defined as any parenchymal hematoma based
on the European Cooperative Acute Stroke Study (ECASS) morphologic definitions (ECASS PH-1 or
PH-2) [17], whereas presence of sICH was based on the ECASS III protocol [4].
2.3. Outcome Measures
The efficacy endpoints were: rate of favorable outcome, defined as a return to the pre-stroke mRS
3 months after AIS, and rate of major neurological improvement which was defined as an improvement
of ≥8 points on the NIHSS from baseline or a NIHSS score of 0 at discharge. The safety endpoints
were: rate of mortality at 3 months, presence of ICH, and presence of sICH.
2.4. Statistical Analysis
Baseline characteristics and outcomes of the two patient groups (IVT+ versus IVT−) were
compared by means of the chi-square test (Fisher’s exact test) for categorical variables and the
Student’s t-test for independent samples when the continuous variables had a normal distribution.
The Mann-Whitney U test was used when the continuous variables had an abnormal distribution and
for ordinal variables. Binary logistic regression was used to explore variables associated with outcome
measures. Data were displayed in tables as means and standard deviations (SD), if not otherwise
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specified. All probability values are two-tailed. A p value of <0.05 was considered to be statistically
significant. Statistical analysis was carried out using the SPSS Statistics, Version 20.0 for Windows
(Chicago, IL, USA).
3. Results
Out of 110 AIS patients with pre-existing moderate and moderately severe disability, 36 underwent
IVT (IVT+), whereas 74 were not treated with IVT (IVT−). Table 1 reports the baseline characteristics
in the two groups. IVT+ patients were older and had more severe strokes at admission compared to
the IVT− patients. Prevalence of cognitive impairment was similar between the two groups (IVT+:
41.2% vs. IVT−: 42.9%, p = 0.9). Use of antiplatelet therapy at time of admission was significantly
more common in the IVT+ patients than in the IVT− group (68.6% vs. 48.6%, p = 0.05). Conversely,
AIS patients who did not receive IVT were more frequently pretreated with anticoagulants (17.6% vs.
2.9%, p = 0.03).
Table 1. Baseline characteristics.
IVT+ (n = 36) IVT− (n = 74) p
Demographic data and baseline clinical characteristics
Age, years 86.0 ± 8.2 79.6 ± 9.3 0.001
Males, n (%) 8 (22.2) 30 (40.5) 0.06
NIHSS score at admission, median (IQR) 10 (5–17.75) 6 (3–15) 0.01
pre-stroke mRS, median (IQR) 3 (3–4) 3.5 (3–4) 0.7
Vascular risk factors
Previous stroke, n (%) 5 (13.9) 15 (20.3) 0.4
Atrial fibrillation, n (%) 20 (55.6) 35 (47.3) 0.4
Hypertension, n (%) 29 (80.6) 63 (85.1) 0.5
Diabetes mellitus, n (%) 9 (25.0) 25 (33.8) 0.3
Hypercholesterolemia, n (%) 12 (33.3) 30 (41.1) 0.4
Current smoking, n (%) 1 (4.8) 5 (10.6) 0.6
Laboratory findings
Serum glucose, mg/dL 139.6 ± 59.0 126.4 ± 60.8 0.3
Creatinine, mg/dL 1.12 ± 0.6 1.01 ± 0.5 0.3
aPTT ratio 1.01 ± 0.1 1.15 ± 0.6 0.1
IVT = intravenous thrombolysis; NIHSS = National Institute of Health Stroke Scale; mRS = modified Rankin Scale;
aPTT = activated Partial Thromboplastin Time; IQR = Interquartile Range.
Table 2 reports the causes of pre-stroke disability in IVT+ and IVT− patients.
Table 2. Causes of pre-stroke disability.
IVT+ (n = 36) IVT− (n = 74) p
Medical conditions 0.7
Multifactiorial, n (%) 12 (33.3) 23 (31.3)
Dementia, n (%) 7 (19.4) 12 (16.2)
Degenerative or traumatic bone diseases, n (%) 6 (16.7) 8 (10.8)
Heart diseases, n (%) 4 (11.1) 9 (12.2)
Cerebrovascular diseases, n (%) 4 (11.1) 8 (10.8)
Cancer, n (%) 0 (0) 7 (9.5)
Other neurological disorders, n (%) 1 (2.8) 4 (5.4)
Other causes, n (%) 2 (5.6) 3 (4.1)
As reported in Table 3, AIS patients with pre-existing moderate and moderately severe disability
had higher rates of favorable outcomes and major neurological improvements when they were treated
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with IVT. In addition, the prevalence of three-month mortality, ICH and sICH did not differ in the
two groups.
Table 3. Efficacy and safety endpoints.
IVT+ (n = 36) IVT− (n = 74) p
Efficacy endpoints
Favorable outcome, n (%) 24 (66.7) 27 (36.5) 0.003
Major neurological improvement, n (%) 13 (39.4) 12 (17.4) 0.01
Safety endpoints
Mortality at 3 months, n (%) 9 (25) 16 (21.6) 0.6
ICH, n (%) 4 (11.1) 4 (5.5) 0.4
sICH, n (%) 2 (5.6) 0 (0) 0.1
IVT = intravenous thrombolysis; ICH = Intracranial Hemorrhage; sICH = symptomatic Intracranial Hemorrhage.
Figure 1 shows the distribution of mRS scores at admission and three months after the stroke
according to IVT treatment.
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Figure 1. Functional status pre and 3 months after stroke according to intravenous thrombolysis (IVT)
treatment on the modified Rankin Scale (mRS).
Significant predictors of efficacy endpoints, other than IVT treatment, by univariate analyses were
the following: NIHSS score at admission (OR 0.89, 95% CI 0.84–0.95, p = 0.001) for favorable outcome
and the serum glucose at admission (OR 0.98, 95% CI 0.97–0.99, p = 0.05) for major neurological
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improvement. Multivariable analyses for efficacy outcomes are shown in Table 4. The statistical
models confirmed that use of IVT was an independent predictor of favorable outcome and major
neurological improvement in AIS patients with pre-existing disability.
Table 4. Multivariable analyses showing the independent predictors of favorable outcome and major
neurological improvement.




NIHSS at admission 0.87 0.81–0.93 0.001




Serum glucose at admission 0.98 0.97–0.99 0.04
4. Discussion
As people continue to live longer and the world’s older population continues to grow at an
unprecedented rate [18]. The prevalence of disability increases with age, affecting 40% of elderlies
over 60 and 75% of those over 80 years old [19]. Similarly, the incidence of AIS doubles with each
decade after the age of 45 years [20]. Since IVT is the standard treatment for patients with AIS, stroke
physicians are frequently called upon to make a decision on whether IVT treatment should be used in
patients with pre-existing disability. Recent international guidelines suggest that IVT treatment may
be reasonable in AIS patients with mRS ≥ 2, however treatment decisions should take into account
relevant factors such as their quality of life, social support, and the need for a caregiver [21]. With these
social factors in mind, the decision to use IVT for treating AIS patients with pre-existing disability
appears to be complex and also raises ethical issues. Presumably, the choice to treat or not to treat with
IVT should involve the patients and their families. To date, the use of IVT in disabled patients remains
uncommon [11,12].
In 2003, Foell et al. compared the outcomes between patients with and without pre-existing
disability undergoing IVT for AIS. Despite a significantly higher mortality rate, disabled patients were
able to return to their pre-stroke level of function as often as patients without pre-existing disability [13].
More recently, Karlinski et al. analyzed the data of all patients (n = 7250) treated with IVT for AIS
between October 2003 and December 2011 that were contributed to the Safe Implementation of
Treatment in Stroke-Eastern Europe (SITS-EAST). Similarly to Foell et al., the authors reported that
mortality was significantly higher in disabled patients than in those with a pre-stroke mRS score of
0, with the odds ratio increasing with higher mRS scores. Pre-existing disability did not increase the
risk of sICH and 1 in 3 previously disabled patients returned to their pre-stroke mRS, thus showing
a favorable outcome. The fact that in this study patients with pre-existing moderate or more severe
disability represented a very small part of the entire sample of AIS patients receiving IVT (2.4%)
confirms that stroke physicians infrequently use recombinant tissue plasminogen activator (rt-PA) in
these subjects [14]. Gensicke et al. replicated the results of Karlinski et al. when examining a large
sample (n = 7430) of IVT-treated stroke patients [15]. In 2018, Zhang et al. showed that following IVT,
a similar portion of AIS patients with and without pre-existing disability return to their premorbid
functional status following IVT. The authors concluded that IVT should be considered in patients with
mild-to-moderate pre-existing disability. However, rt-PA use was uncommon in this sample of AIS
patients with moderate and moderately severe pre-stroke disability [16]. Altogether, these studies
focused on the role of pre-existing disability on outcomes in AIS patients receiving IVT but did not
explore the efficacy and safety of IVT in AIS patients with pre-stroke disability, which was the aim
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of our study. In fact, we compared disabled patients treated with and without IVT. Because little is
known regarding patients with higher mRS score, we decided to include only subjects with moderate
and moderately severe disability (mRS score = 3 or 4). In our cohort, the use of rt-PA was associated
with increased age and a more severe stroke at admission in disabled patients. Although both these
variables are known as independent predictors of poor outcome, IVT+ patients had more than seven
times (OR 7.26, 95% CI 2.51–21.02) the odds of favorable outcome and more than three times (OR 3.70,
95% CI 1.32–10.35) the odds of major neurological improvement than IVT− ones. Two in three disabled
patients returned to their pre-stroke functional status when treated with IVT. In particular, almost
half (42%) of the patients with a pre-stroke mRS score of 3 returned to their pre-existing moderate
disability if they received IVT. A similar outcome occurred in only 18% of moderately disabled patients
that did not receive rt-PA. Although less prominent, the efficacy of IVT on three-month mRS was also
confirmed in patients with moderately severe pre-stroke disability. These results are relevant because
a recent population-based, prospective cohort study found that if patients with mild-to-moderate
premorbid disability accumulate additional disability as a result of a new ischemic stroke, they had far
worse five-year mortality, institutionalization outcomes, and higher five-year health/social-care costs,
than those who retained their premorbid disability [22].
IVT treatment and serum glucose at admission were the only two independent predictors of major
neurological improvement in our sample of disabled patients. Notably, 39.4% of disabled patients
receiving rt-PA showed a significantly improved NIHSS score at discharge. The prevalence of major
neurological improvement was greatly lower in IVT− patients.
Previously disabled patients do not seem to be different from the others regarding the better
outcome related to onset-to-treatment interval. In fact, a recent study by Nolte et al. showed that
prehospital start of IVT treatment on mobile stroke units, as compared with in-hospital care, may
translate into better clinical outcomes in patients with pre-stroke dependency [23].
IVT treatment did not increase the risk of three-month mortality in disabled patients. In fact,
mortality rate was comparable between IVT+ and IVT− patients, even though subjects in the
IVT+ group were significantly older. Only two studies reported the three-month mortality rate
in patients receiving IVT with a pre-stroke mRS score of 3–5. Both Karlinski et al. (48.4%) and
Gensicke et al. (38.7%) observed a much higher percentage of death with respect to our study
(25%) [12,13]. As expected, we observed a trend for ICH and sICH events being more common in
patients receiving than in those not receiving IVT. The rate of sICH in our group of disabled IVT+
patients was similar to that reported by Gensicke et al. (5.6% vs. 4.8%), whereas sICH events were
observed more frequently by Karlinski et al. (11.7%) [14,15].
We are aware that our investigation was a retrospective observational study with a small sample
size. In addition, measures of outcome were obtained by physicians that were not blinded on IVT
treatment. Furthermore, the raters of the mRS at three months were not blinded to the pre-stroke mRS,
which may have had influenced their rating, and the assessment of the pre-stroke disability with mRS
is not completely reliable, due to its intrinsic sensitivity and to interobserver variability [24,25]. Finally,
although all patients were qualified for IVT, we were certainly unable to detect all prognostic factors
and the baseline differences showed in Table 2 may have missed other unknown intergroup differences,
which in theory could have skewed the IVT+ and IVT− population, leading to IVT use only in patients
with a better prognosis. However, despite these limitations we demonstrated for the first time that
disabled patients affected by AIS significantly improve after IVT. As a consequence, moderate and
moderately severe disability alone should not be considered, per se, as a contraindication to IVT
treatment. A randomized controlled trial will be needed to validate our results.
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